connect with kpcc
-
.
.
- . .
- eptinezumab is in phase iii trials. its maker plans to submit an application with the fda later this year. it is for chronic migraine prevention. . .
cnn sans ™ & © 2016 cable news network. .
-
.
over the years, i�ve talked to reporters who are solidly addicted to obfuscations. like any addict, they have an army of excuses to rationalize their behavior. .